ArticleAnnals of translational medicine2022
The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 7 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.Journal of gastroenterology · 2026Guideline
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Comparing potassium-competitive acid blocker-based therapies forFrontiers in physiology · 2026Pooled it
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- First-line Eradication of Helicobacter pylori Infection with High-Dose Amoxicillin and Vonoprazan: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Pooled it
- Efficacy and safety of Vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis.BMC infectious diseases · 2024Pooled it
- Vonoprazan-amoxicillin dual therapy forSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.BMC gastroenterology · 2024Trial
- Vonoprazan-amoxicillin dual therapy forWorld journal of gastroenterology · 2024Trial
- Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial.BMC gastroenterology · 2024Trial
- Vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world, retrospective study.Medicine · 2026Article
- Efficacy and safety of potassium-competitive acid blockers in eradicatingCaspian journal of internal medicine · 2026Review
- Vonoprazan-related adverse events: a pharmacovigilance study based on the FDA adverse event reporting system.Frontiers in medicine · 2025Article
- Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy forTherapeutic advances in gastroenterology · 2025Article
- Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication ofFrontiers in pharmacology · 2025Article
- Article
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- Ten-day vonoprazan-amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-lineTherapeutic advances in gastroenterology · 2024Article
- P-CABTherapeutic advances in gastroenterology · 2024Article
- Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication ofJournal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of vonoprazan (VPZ) has improved the Methods: This experiment involved an open, multicenter, randomized, and parallel controlled clinical investigation. A total of 230 newly diagnosed Results: The regimen effectiveness was 63.5% (54/85) in the H-VA group, 58.3% (49/84) in the L-VA group, and 60.7% (37/61) in the VAC group, according to intention to treat (ITT) analysis. According to per protocol (PP) analysis, the eradication rate of the H-VA group was 65.1% (54/83), that of the L-VA group was 66.2% (49/74), and that of the VAC group was 64.9% (37/57). There was no discernible difference in the eradication rate across the 3 regimens, as shown by the results of ITT analysis (χ Conclusions: None of the 7-day elimination regimens investigated in this study, which included the acid-suppressing medicine VPZ and either a dual treatment paired with amoxicillin, or a triple treatment combined with amoxicillin and clarithromycin, achieved an acceptable eradication rate of Trial Registration: Chinese Clinical Trial Registry identifier: ChiCTR2000040955.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.